Glasgow Asthma and Allergy Study

Asthma Clinical Trial

— GLAAS  

Official title:

Cross Sectional Study to Evaluate and Associate Clinical and Laboratory Features of People With Allergic and Non-allergic Asthma

Clinical Trial Details — Status: Completed

Administrative data

• NCT number: NCT01618318
• Other study ID #: 12/WS/0049
• Status: Completed
• Phase: N/A
• First received: June 8, 2012
• Last updated: December 4, 2013
• Start date: June 2012
• Est. completion date: October 2013

Study information

• Verified date: December 2013
• Source: National Services for Health Improvement Ltd
• Contact: n/a
• Is FDA regulated: No
• Health authority: United Kingdom: Research Ethics Committee
• Study type: Observational

Clinical Trial Summary

In the past, doctors separated people with asthma into two groups, those with "allergic asthma" (about 2/3rds of people) and those with "non-allergic asthma". These labels are not much used now as the treatments for all people with asthma don't depend on this classification. However, new treatments for asthma may become available and the classification may again become important. It could be useful for clinicians to know how to identify which patients are likely to benefit from particular treatments.

Additionally, some new blood tests are becoming available and some of these might help to categorise the type of asthma people have. What the study hopes to do is to identify patient features which make a diagnosis of "allergic asthma" more likely and to see which new blood tests are most likely to be helpful in confirming this diagnosis.

Recruitment information / eligibility

• Status: Completed
• Enrollment: 105
• Est. completion date: October 2013
• Est. primary completion date: October 2013
• Accepts healthy volunteers: No
• Gender: Both
• Age group: 18 Years and older

Eligibility

Inclusion Criteria:

• Male and female patients aged 18 years old and over with a diagnosis of asthma and having received at least two prescriptions for any asthma medication in the last 12 months, who have signed an informed consent form prior to initiation of any study-related procedure

Exclusion Criteria:

• under 18 years

• current smokers

• unwilling or unable to give informed consent

• a clinical diagnosis of COPD

• a history of anaphylaxis (skin prick test)

• participated in any clinical study in the last 12 months

Study Design

Observational Model: Cohort, Time Perspective: Cross-Sectional

Related Conditions & MeSH terms

• Allergy
• Asthma
• Hypersensitivity

Locations

Country	Name	City	State
United Kingdom	NSHI Ltd	Dartford	Kent

Sponsors (2)

Lead Sponsor	Collaborator
National Services for Health Improvement Ltd	Merck Sharp & Dohme Corp.

Country where clinical trial is conducted

United Kingdom, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Serum periostin level	This is a cross sectional study. Participants will be assessed and tests conducted at a single visit	1 day	No
Secondary	skin prick test		1 day	No
Secondary	Serum total IgE		1 day	No
Secondary	Blood eosinophil count		1 day	No
Secondary	Blood neutrophil count		1 day	No
Secondary	Blood CD4 cells that are positive for CRTh2		1 day	No
Secondary	Blood eosinophils expressing CRTh2		1 day	No
Secondary	Spirometry		1 day	No